Cargando…

Impact of AJCC prognostic staging on prognosis and postmastectomy radiotherapy decision-making in hormone receptor-positive and HER2-positive breast cancer

BACKGROUND: The role of postmastectomy radiotherapy (PMRT) in patients with node-positive hormone receptor-positive (HoR) and HER2-positive breast cancer (BC) regarding AJCC pathological prognostic staging (PPS) has not been fully determined. This study aimed to validate PPS in patients with node-po...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Guan-Qiao, Yu, Yang, Zhang, Wen-Wen, Zhou, Ping, Lian, Chen-Lu, He, Zhen-Yu, Wu, San-Gang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035436/ https://www.ncbi.nlm.nih.gov/pubmed/35466375 http://dx.doi.org/10.1093/bjsopen/zrac025

Ejemplares similares

The effect of postmastectomy radiotherapy in node-positive triple-negative breast cancer
por: Zhang, Lei, et al.
Publicado: (2020)

The Predictive Effect of the 8th AJCC Pathological Prognostic Staging on the Benefit of Postmastectomy Radiotherapy in N2/N3 Breast Cancer
por: Yang, Shi-Ping, et al.
Publicado: (2022)

Triple-negative breast cancer outcomes: Does AJCC 8th staging improve chemotherapy decision-making
por: Lian, Chen-Lu, et al.
Publicado: (2021)

Real-world impact of postmastectomy radiotherapy in T1–2 breast cancer with one to three positive lymph nodes
por: Li, Feng-Yan, et al.
Publicado: (2020)

Clinical decision making in postmastectomy radiotherapy in node negative breast cancer
por: Barrientos, Rodrigo, et al.
Publicado: (2018)

Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial
por: Dieci, Maria Vittoria, et al.
Publicado: (2019)

Prognostic validation and therapeutic decision‐making of the AJCC eighth pathological prognostic staging for T3N0 breast cancer after mastectomy
por: Wu, San‐Gang, et al.
Publicado: (2020)

Effects of postmastectomy radiotherapy on prognosis in different tumor stages of breast cancer patients with positive axillary lymph nodes
por: Jia, Miao-Miao, et al.
Publicado: (2014)

Number of negative lymph nodes can predict survival of breast cancer patients with four or more positive lymph nodes after postmastectomy radiotherapy
por: Wu, San-Gang, et al.
Publicado: (2014)

Postmastectomy Radiotherapy Improves Disease-Free Survival of High Risk of Locoregional Recurrence Breast Cancer Patients with T1-2 and 1 to 3 Positive Nodes
por: He, Zhen-Yu, et al.
Publicado: (2015)

Correction: Postmastectomy Radiotherapy Improves Disease-Free Survival of High Risk of Locoregional Recurrence Breast Cancer Patients with T1-2 and 1 to 3 Positive Nodes
por: He, Zhen-Yu, et al.
Publicado: (2015)

Is Postmastectomy Radiotherapy Really Needed in Breast Cancer Patients with Many Positive Axillary Lymph Nodes?
por: Marinko, Tanja, et al.
Publicado: (2018)

Non-compliance with a postmastectomy radiotherapy guideline: Decision tree and cause analysis
por: Razavi, Amir R, et al.
Publicado: (2008)

Automated treatment planning of postmastectomy radiotherapy
por: Kisling, Kelly, et al.
Publicado: (2019)

Stakeholders’ Perspectives on Postmastectomy Breast Reconstruction: Recognizing Ways to Improve Shared Decision Making
por: Hasak, Jessica M., et al.
Publicado: (2017)

Importance of Shared Decision-Making for Vulnerable Populations: Examples from Postmastectomy Breast Reconstruction
por: Grabinski, Victoria F., et al.
Publicado: (2018)

The Prognosis of Single Hormone Receptor-Positive Breast Cancer Stratified by HER2 Status
por: Zhao, Hengqiang, et al.
Publicado: (2021)

Predictive Value of Molecular Subtyping for Locoregional Recurrence in Early-Stage Breast Cancer with N1 without Postmastectomy Radiotherapy
por: Wen, Ge, et al.
Publicado: (2016)

Effect of postmastectomy radiotherapy on triple-negative breast cancer with T1-2 and 1-3 positive axillary lymph nodes: a population-based study using the SEER 18 database
por: Zhang, Jie, et al.
Publicado: (2019)

Dosimetric and Radiobiological Comparison of Five Techniques for Postmastectomy Radiotherapy with Simultaneous Integrated Boost
por: Tang, Du, et al.
Publicado: (2020)

Application of thermoplastic elastomer (TPE) bolus in postmastectomy radiotherapy
por: Gong, Pan, et al.
Publicado: (2022)

Impact of Breast Cancer Subtype Defined by Immunohistochemistry Hormone Receptor and HER2 Status on the Incidence of Immediate Postmastectomy Reconstruction
por: Wu, Wei, et al.
Publicado: (2016)

Real-world outcomes of postmastectomy radiotherapy in breast cancer patients with 1–3 positive lymph nodes: a retrospective study
por: Chitapanarux, Imjai, et al.
Publicado: (2014)

Local and regional recurrence following mastectomy in breast cancer patients with 1–3 positive nodes: implications for postmastectomy radiotherapy volume
por: Park, Shin-Hyung, et al.
Publicado: (2018)

Intrinsic subtypes and therapeutic decision-making in hormone receptor-positive/HER2-negative metastatic breast cancer with visceral crisis: A case report
por: Schettini, Francesco, et al.
Publicado: (2022)

Number of Negative Lymph Nodes Can Predict Survival after Postmastectomy Radiotherapy According to Different Breast Cancer Subtypes
por: Wu, San-Gang, et al.
Publicado: (2015)

Impact of the 21-gene expression assay on treatment decisions and clinical outcomes in breast cancer with one to three positive lymph nodes
por: Li, Guan-Qiao, et al.
Publicado: (2023)

The role of postmastectomy radiotherapy in clinically node-positive, stage II-III breast cancer patients with pathological negative nodes after neoadjuvant chemotherapy: an analysis from the NCDB
por: Liu, Jieqiong, et al.
Publicado: (2015)

Dosimetric assessment of brass mesh bolus for postmastectomy photon radiotherapy
por: Manger, Ryan, et al.
Publicado: (2016)

Metformin increases survival in hormone receptor-positive, HER2-positive breast cancer patients with diabetes
por: Kim, Hee Jeong, et al.
Publicado: (2015)

Effect of postmastectomy radiotherapy on pT(1-2)N(1) breast cancer patients with different molecular subtypes()
por: Guo, Xin-Yuan, et al.
Publicado: (2021)

Comparison of Treatment Outcome between Hypofractionated Radiotherapy and Conventional Radiotherapy in Postmastectomy Breast Cancer
por: Tovanabutra, Chokaew, et al.
Publicado: (2020)

Prognostic Significance of O-GlcNAc and PKM2 in Hormone Receptor-Positive and HER2-Nonenriched Breast Cancer
por: Kuo, Wen-Ling, et al.
Publicado: (2021)

Combination of radiotherapy and targeted therapy for HER2-positive breast cancer brain metastases
por: Yang, Xiaojing, et al.
Publicado: (2023)

Trastuzumab Provides a Comparable Prognosis in Patients With HER2-Positive Breast Cancer to Those With HER2-Negative Breast Cancer: Post Hoc Analyses of a Randomized Controlled Trial of Post-Mastectomy Hypofractionated Radiotherapy
por: Sun, Guang-Yi, et al.
Publicado: (2021)

Decreased expression of stomatin predicts poor prognosis in HER2-positive breast cancer
por: Chen, Chin-Yau, et al.
Publicado: (2016)

Trastuzumab improves locoregional control in HER2-positive breast cancer patients following adjuvant radiotherapy
por: Cao, Lu, et al.
Publicado: (2016)

21-Gene Recurrence Score Assay Could Not Predict Benefit of Post-mastectomy Radiotherapy in T1-2 N1mic ER-Positive HER2-Negative Breast Cancer
por: Zhang, Wen-Wen, et al.
Publicado: (2019)

Postmastectomy Radiotherapy for Locally Advanced Breast Cancer Receiving Neoadjuvant Chemotherapy
por: Meattini, Icro, et al.
Publicado: (2014)

The effects of postoperative radiotherapy on survival outcomes in patients under 65 with estrogen receptor positive tubular breast carcinoma
por: Chen, Jian-Xian, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_urd44nb2lc3dnv3a84fq4p5k4s